BRPI0416268A - composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla - Google Patents

composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla

Info

Publication number
BRPI0416268A
BRPI0416268A BRPI0416268-4A BRPI0416268A BRPI0416268A BR PI0416268 A BRPI0416268 A BR PI0416268A BR PI0416268 A BRPI0416268 A BR PI0416268A BR PI0416268 A BRPI0416268 A BR PI0416268A
Authority
BR
Brazil
Prior art keywords
methods
symptoms associated
delta
multiple sclerosis
treating symptoms
Prior art date
Application number
BRPI0416268-4A
Other languages
English (en)
Inventor
Robert E Dudley
Original Assignee
Unimed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unimed Pharmaceuticals Inc filed Critical Unimed Pharmaceuticals Inc
Publication of BRPI0416268A publication Critical patent/BRPI0416268A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSIçõES DE DELTA-9-THC E MéTODOS PARA O TRATAMENTO DE SINTOMAS ASSOCIADOS à ESCLEROSE MúLTIPLA. São proporcionados métodos, inter alia, para o tratamento e/ou prevenção de sintomas associados á esclerose múltipla e relapso de MS.
BRPI0416268-4A 2003-11-05 2004-11-04 composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla BRPI0416268A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51747903P 2003-11-05 2003-11-05
US98222904A 2004-11-03 2004-11-03
PCT/US2004/037149 WO2005044093A2 (en) 2003-11-05 2004-11-04 Delta-9- the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
BRPI0416268A true BRPI0416268A (pt) 2007-12-11

Family

ID=34576802

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416268-4A BRPI0416268A (pt) 2003-11-05 2004-11-04 composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla

Country Status (8)

Country Link
US (1) US20060167084A1 (pt)
EP (1) EP1696929A4 (pt)
JP (1) JP2007510736A (pt)
AU (1) AU2004287495A1 (pt)
BR (1) BRPI0416268A (pt)
CA (1) CA2544900A1 (pt)
MX (1) MXPA06005015A (pt)
WO (1) WO2005044093A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
EP1827393A4 (en) * 2004-12-09 2012-04-18 Insys Therapeutics Inc AT ROOM TEMPERATURE, STABLE DRONABINOL FORMULATIONS
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060639A1 (en) * 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
US20080175902A1 (en) * 2006-11-30 2008-07-24 University Of Plymouth Methods for slowing the progression of multiple sclerosis
US20080181942A1 (en) * 2006-11-30 2008-07-31 University Of Plymouth Delta-9-THC compositions and methods for treating symptoms associated with multiple sclerosis
JP2010535774A (ja) * 2007-08-06 2010-11-25 インシス セラピューティクス インコーポレイテッド 経口カンナビノイド液体製剤および治療方法
EP3834869B1 (en) 2010-12-22 2024-06-05 Syqe Medical Ltd. System for drug delivery
EP2797880B1 (en) * 2011-12-27 2017-03-01 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating epilepsy
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
RU2721064C2 (ru) 2014-06-30 2020-05-15 Сике Медикал Лтд. Ингалятор с регулированием потока
CN113616883B (zh) 2014-06-30 2023-06-06 Syqe医药有限公司 向受试者肺部递送植物材料中的至少一药理活性剂的系统
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
IL273507B2 (en) 2014-06-30 2024-06-01 Syqe Medical Ltd Methods, devices and systems for administering active substances through the lungs
AU2015283589B2 (en) 2014-06-30 2019-09-12 Syqe Medical Ltd. Method and device for vaporization and inhalation of isolated substances
RU2723335C2 (ru) 2014-06-30 2020-06-09 Сике Медикал Лтд. Дозовый картридж для ингалятора
CA3009599A1 (en) 2016-01-06 2017-07-13 Syqe Medical Ltd. Low dose therapeutic treatment
PT3474844T (pt) 2016-06-28 2022-11-08 Trichomeshell Ltd Uma forma de dosagem para ser vaporizada e fumada
US10307392B2 (en) 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
US10722545B2 (en) 2018-01-01 2020-07-28 Alexander Kariman Compound and method for treatment of movement disorders
CA3154135A1 (en) 2019-09-16 2021-03-25 Vapor Cartridge Technology Llc Drug delivery system with stackable substrates
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US6328992B1 (en) * 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
US6113940A (en) * 1997-03-03 2000-09-05 Brooke; Lawrence L. Cannabinoid patch and method for cannabis transdermal delivery
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
JP2003504321A (ja) * 1999-07-08 2003-02-04 オーランド・ハン リポソーム被包カンナビノイドの肺送達
US20020111377A1 (en) * 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
US6503532B1 (en) * 2001-04-13 2003-01-07 Murty Pharmaceuticals, Inc. Pharmaceutical composition containing tetrahydrocannabinol and a transdermal/transcutaneous delivery method thereof
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition

Also Published As

Publication number Publication date
EP1696929A2 (en) 2006-09-06
US20060167084A1 (en) 2006-07-27
CA2544900A1 (en) 2005-05-19
MXPA06005015A (es) 2007-11-22
JP2007510736A (ja) 2007-04-26
WO2005044093A2 (en) 2005-05-19
EP1696929A4 (en) 2010-02-24
WO2005044093A3 (en) 2005-09-22
AU2004287495A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE554114T1 (de) Copolymer mit zwitterionischen einheiten und anderen einheiten, das copolymer umfassende zusammensetzung und verwendung
UA85559C2 (en) Aminobenzophenone compounds
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MXPA03008738A (es) Combinaciones inmunoterapeuticas para el tratamiento de tumores que sobre-expresan glangliosidos.
PT2275097T (pt) Composições que incluem canabinoides para tratamento de náuseas, vómitos, émese, enjoo ou condições idênticas
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
TW200518769A (en) Use of calcitonin in osteoarthritis
LTC2805723I2 (lt) Kladribino režimas, skirtas išsėtinei sklerozei gydyti
DE60312211D1 (de) Haarbehandlungsmittel
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
SE0301650D0 (sv) Novel compounds
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
BR0214799B1 (pt) instalação flutuante para tratamento de hidrocarbonetos.
TR200705146T1 (tr) Monoamin Yükselmesinin Engellenmesi
DE602004013011D1 (de) Haarbehandlungszusammensetzungen
BRPI0506631B8 (pt) combinações, composição farmacêutica e usos das combinações
WO2007076320A3 (en) Compounds
BRPI0507157A (pt) uso de fator viia ou de um equivalente de fator viia, kit de partes para tratamento de trauma, e, métodos para tratar trauma e para prevenir, tratar trauma

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.